Iopromide


Thông tin thuốc gốc
Chỉ định và Liều dùng
Intra-arterial
Cerebral arteriography
Adult: As 300 mg iodine/mL: Carotid artery visualisation: 3-12 mL. Vertebral artery visualisation: 4-12 mL. Aortic arch inj: 20-50 mL. Max dose for procedure: 150 mL.

Intra-arterial
Aortography and visceral angiography
Adult: As 370 mg iodine/mL: Volume and rate of administration are based on the blood flow and specific characteristics of vessels being studied. Max dose for procedure: 225 mL.

Intra-arterial
Peripheral arteriography
Adult: As 300 mg iodine/mL: Subclavian or femoral artery: 5-40 mL. Aortic bifurcation for distal runoff: 25-50 mL. Max dose for procedure: 250 mL.

Intra-arterial
Coronary arteriography and left ventriculography
Adult: As 370 mg iodine/mL: Left or right coronary artery: 3-14 mL. Left ventricle: 30-60 mL. Max dose for procedure: 225 mL.

Intravenous
Contrast-enhanced computerized tomography
Adult: As 300 mg of iodine/mL: Head: 50-200 mL via IV inj. Max dose for procedure: 200 mL. Body: As single phase inj, 50-200 mL via IV bolus inj; 100-200 mL via rapid infusion. Max dose for procedure: 200 mL. As multiple phase inj, 50-200 mL via IV inj. Max dose for procedure: 200 mL. As 370 mg of iodine/mL: Head: 41-162 mL via IV inj. Max dose for procedure: 162 mL. Body: As single phase inj, 41-162 mL via IV bolus inj; 81-162 mL via rapid infusion. Max dose for procedure: 162 mL. As multiple phase inj, 41-162 mL via IV inj. Max dose for procedure: 162 mL.
Child: >2 years As 300 mg iodine/mL: 1-2 mL/kg. Max dose for procedure: 3mL/kg.

Intravenous
Excretory urography
Adult: As 300 mg iodine/mL: 1 mL/kg via IV infusion. Max dose for procedure: 100 mL.
Child: >2 years As 300 mg iodine/mL: 1-2 mL/kg. Max dose for procedure: 3mL/kg.
Chống chỉ định
Intrathecal administration.
Thận trọng
Patient with a history of hypersensitivity to contrast dye or iodine, and with known allergic disorders (e.g. bronchial asthma, hay fever, food allergies); advanced vascular disease, CV disease or heart failure, diabetes mellitus, thyroid disease, multiple myeloma, sickle cell disease, phaeochromocytoma, and dehydration. Renal and hepatic impairment. Pregnancy and lactation.
Phản ứng phụ
Significant: Extravasation, acute kidney injury, renal failure, severe cutaneous adverse reactions (e.g. Stevens-Johnson syndrome, toxic epidermal necrolysis, acute generalised exanthematous pustulosis, drug reaction with eosinophilia and systemic symptoms).
Cardiac disorders: Chest pain.
Eye disorders: Blurred vision.
Gastrointestinal disorders: Nausea, vomiting, abdominal pain.
General disorders and administration site conditions: Injection site pain.
Nervous system disorders: Headache, dizziness, dysgeusia.
Vascular disorders: Vasodilation, hypertension.
Potentially Fatal: Anaphylactic reactions. Rarely, thromboembolic events.
Intra-arterial/IV/Parenteral: B
MonitoringParameters
Monitor renal function, blood pressure, and hydration; signs of extravasation and hypersensitivity reactions during administration.
Quá liều
Symptoms: Fluid and electrolyte imbalance; CV and pulmonary complications; renal impairment. Management: Symptomatic and supportive treatment.
Tương tác
May increase the risk of lactic acidosis induced by biguanides (e.g. metformin). Increased prevalence of delayed hypersensitivity reactions with interleukins.
Lab Interference
May affect thromboplastin time, thrombin activity, and the accuracy of thyroid function tests assessment.
Tác dụng
Description: Iopromide is a nonionic iodinated radiographic contrast medium. It allows visualisation of internal body structures by opacifying the path of its flow.
Pharmacokinetics:
Distribution: Rapidly distributed in the extracellular fluid. Volume of distribution: 16 L. Plasma protein binding: 1%.
Excretion: Via urine (97% as unchanged drug); faeces (2%). Elimination half-life: 2 hours.
Đặc tính

Chemical Structure Image
Iopromide_01

Source: National Center for Biotechnology Information. PubChem Compound Summary for CID 3736, Iopromide. https://pubchem.ncbi.nlm.nih.gov/compound/Iopromide. Accessed Oct. 26, 2020.

Bảo quản
Store at 25°C. Protect from light.
Phân loại ATC
V08AB05 - iopromide ; Belongs to the class of watersoluble, nephrotropic, low osmolar preparations used as X-ray contrast media.
References
Anon. Iopromide. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. https://online.lexi.com. Accessed 17/08/2020.

Buckingham R (ed). Iopromide. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 17/08/2020.

Iopromide. Gold Standard Drug Database in ClinicalKey [online]. Elsevier Inc. https://www.clinicalkey.com/. Accessed 17/08/2020.

Ultravist 300/370 Solution for Injection/Infusion (Bayer AG). National Pharmaceutical Regulatory Agency - Ministry of Health Malaysia. https://www.npra.gov.my/. Accessed 17/08/2020.

Ultravist 370 (Bayer plc). MHRA. https://products.mhra.gov.uk/. Accessed 17/08/2020.

Ultravist Injection (Bayer Healthcare Pharmaceuticals Inc.). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/. Accessed 17/08/2020.

Thông báo miễn trừ trách nhiệm: Thông tin này được MIMS biên soạn một cách độc lập dựa trên thông tin của Iopromide từ nhiều nguồn tài liệu tham khảo và được cung cấp chỉ cho mục đích tham khảo. Việc sử dụng điều trị và thông tin kê toa có thể khác nhau giữa các quốc gia. Vui lòng tham khảo thông tin sản phẩm trong MIMS để biết thông tin kê toa cụ thể đã qua phê duyệt ở quốc gia đó. Mặc dù đã rất nỗ lực để đảm bảo nội dung được chính xác nhưng MIMS sẽ không chịu trách nhiệm hoặc nghĩa vụ pháp lý cho bất kỳ yêu cầu bồi thường hay thiệt hại nào phát sinh do việc sử dụng hoặc sử dụng sai các thông tin ở đây, về nội dung thông tin hoặc về sự thiếu sót thông tin, hoặc về thông tin khác. © 2021 MIMS. Bản quyền thuộc về MIMS. Phát triển bởi MIMS.com
  • Ultravist
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in